MedPath

Zinc

Generic Name
Zinc
Brand Names
Vitafol-one, Wilzin
Drug Type
Small Molecule
Chemical Formula
Zn
CAS Number
7440-66-6
Unique Ingredient Identifier
J41CSQ7QDS
Background

A metallic element of atomic number 30 and atomic weight 65.38. It is a necessary trace element in the diet, forming an essential part of many enzymes, and playing an important role in protein synthesis and in cell division. Zinc deficiency is associated with anemia, short stature, hypogonadism, impaired wound healing, and geophagia. It is identified by the symbol Zn .

A newer study suggests implies that an imbalance of zinc is associated with the neuronal damage associated with traumatic brain injury, stroke, and seizures .

Understanding the mechanisms that control brain zinc homeostasis is, therefore, imperative to the development of preventive and treatment regimens for these and other neurological disorders .

In addition to the above, recent review articles have already demonstrated the important role of zinc in the pathophysiology and treatment of affective disorders, plus discussed the potential value of zinc as a marker of these diseases . Most recently, research has shown that polymorphism of the common polymorphism in zinc transporter SLC30A8/ZnT8 may increase susceptibility to type 2 diabetes provided novel insights into the role of zinc in diabetes .

Indication

Zinc can be used for the treatment and prevention of zinc deficiency/its consequences, including stunted growth and acute diarrhea in children, and slowed wound healing. It is also utilized for boosting the immune system, treating the common cold and recurrent ear infections, as well as preventing lower respiratory tract infections .

Associated Conditions
Candidiasis, Common Cold, Diaper Dermatitis, Diaper Rash, Eye redness, Iron Deficiency (ID), Ocular Irritation, Skin Irritation, Sunburn, Wilson's Disease, Zinc Deficiency
Associated Therapies
Dietary and Nutritional Therapies, Dietary supplementation

Telomir Pharmaceuticals' Telomir-1 Shows Copper-Binding Potential for Wilson's Disease Treatment

• Telomir Pharmaceuticals' Telomir-1 demonstrated significant copper-binding affinity in preclinical studies, suggesting its potential for treating Wilson's disease. • The company plans IND-enabling safety studies in Q2 2025, targeting an IND submission by Q4 2025, with human clinical trials expected in H1 2026. • Telomir discontinued an osteoarthritis study in dogs due to ethical concerns, opting for a new study design with naturally affected elderly dogs. • The company is also expanding research into Type 2 diabetes, Progeria, cancer, and Alzheimer's, supported by recent financing secured at a 20% premium.

University of Minnesota Trial Finds Hydroxychloroquine No Better Than Placebo in Preventing COVID-19

A University of Minnesota trial has concluded that hydroxychloroquine is no more effective than a placebo in preventing COVID-19 after exposure, with 40% of participants experiencing non-serious side effects.
© Copyright 2025. All Rights Reserved by MedPath